<DOC>
	<DOC>NCT00496847</DOC>
	<brief_summary>PERIOGEN, containing rhPDGF and -beta-TCP, promotes gingival healing and corrects periodontal defects. This study will test the safety and efficacy of PERIOGEN in the treatment of periodontal disease</brief_summary>
	<brief_title>Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect</brief_title>
	<detailed_description>Sixty eligible patients with periodontal defect will randomly receive either beta-TCP implantation (control group) or PERIOGEN implantation, containing beta-TCP and rhPDGF (drug group). The specified primary and secondary end points related to efficacy and safety will be assessed during 6 months study period.</detailed_description>
	<criteria>1. Probing depth ≥7 mm at baseline 2. Presence of ≥4 mm vertical bone defect with at least 1 bony wall after surgical debridement. 3. Adequate keratinized tissue to permit complete tissue coverage of defect. 4. Radiographic base of defect ≥3 mm coronal to the apex of the tooth. 1. Failure to maintain adequate oral hygiene (plaque index&gt;2) 2. Pregnant and lactating women 3. History of oral cancer or HIV 4. Periodontal surgery on treatmenttargeted tooth within the last year. 5. Tooth mobility greater than grade II. 6. Study tooth exhibiting a class III furacation defect 7. Localized aggressive periodontitis 8. Radiographic signs of untreated acute infection at the surgical site 9. Recent history of smoking more than 20 cigarettes/day 10. Known allergy to E.coliderived products 11. Using an investigational therapy within the past 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>rhPDGF,</keyword>
	<keyword>periodontal disease</keyword>
</DOC>